PPLPHARMA · NSE
Piramal Pharma Limited
₹239.3
-0.15% (-₹0.35)
Prev. close
₹239.65
Volume
39,10,760
Delivery %
45.6%
As of
20 Nov 2026
Price history
Analyst sentiment
Analysts lean bullish
1 analyst stance · last 90 days · one per analyst
Trackable
none in range
Long-Horizon
none in range
Commentary
1 · 1 bull / 0 neutral / 0 bear
Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded
Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Bullish on Piramal Pharma for intraday trading; recommends buying at ₹210.50 with a target of ₹223 and a stop loss at ₹2…” | Vaishali ParekhPrabhudas Lilladher | Piramal Pharma | HIT | |
| “Bullish on Piramal Pharma, recommending a buy at ₹172–176 with a target of ₹188 and a stop-loss at ₹167. After five quar…” | Dharmesh ShahICICI Securities | Piramal Pharma | HIT | |
| “Recommends buying Piramal Pharma Ltd with an entry range of ₹188-190, a stop loss at ₹185, and a target price of ₹200. T…” | Ganesh DongreAnand Rathi | Piramal Pharma Ltd | NOT TRIGGERED | |
| “Bullish on Piramal Pharmaceuticals with a target price of ₹250 per share. Despite transitory near-term pressure in CDMO …” | Goldman Sachs AnalysisGoldman Sachs Group Inc. | Piramal Pharma Ltd | MISS | |
| “Recommends buying Piramal Pharma at ₹203, targeting ₹215, with a stop loss at ₹199 for intraday trading.” | Vaishali ParekhPrabhudas Lilladher | Piramal Pharma | MISS | |
| “Bullish on Piramal Pharma, setting a target of ₹260, indicating an almost 30% potential upside. The stock's valuation di…” | Jefferies AnalysisJefferies | Piramal Pharma Ltd | MISS | |
| “ICICI Securities recommends buying Piramal Pharma with a target price of ₹265. The call is based on the company's strong…” | ICICI Securities AnalysisICICI Securities | Piramal Pharma Ltd | MISS | |
| “Recommends buying Piramal Pharma at ₹208, targeting ₹220, with a stop loss at ₹200.” | Vaishali ParekhPrabhudas Lilladher | Piramal Pharma Ltd | MISS | |
| “Recommends buying Piramal Pharma with a target price of Rs 232 and a stop loss at Rs 218 for short-term trading.” | Kunal BothraIndependent | Piramal Pharma Ltd | MISS | |
| “Bullish on Piramal Pharma with a target of ₹232 and a stop loss at ₹218, recommending a buy.” | Kunal BothraIndependent | Piramal Pharma Ltd | MISS | |
| “Bullish on Piramal Pharma, recommending a buying range of ₹193-203 with a 12-month target price of ₹229, indicating clos…” | Bajaj Broking AnalysisBajaj Broking Research | Piramal Pharma Ltd | PENDING | |
| “Choice Institutional Equities recommends buying Piramal Pharma with a target price of ₹315, based on a positive outlook …” | Choice Institutional Equities AnalysisChoice Institutional Equities | Piramal Pharma | MISS | |
| “Bullish on Piramal Pharma for the short term, recommending a buy at CMP ₹232 with a target of ₹250 and a stop-loss at ₹2…” | Riyank AroraMehta Equities | Piramal Pharma Ltd | PENDING | |
| “Recommends buying Piramal Pharma at ₹232.65, targeting ₹250, with a stop loss at ₹224. This is a stock-specific trade ba…” | Sumeet BagadiaChoice Equity Broking | Piramal Pharma Ltd | MISS | |
| “Recommends buying Piramal Pharma Ltd at ₹233, targeting ₹250, with a stop loss at ₹225 for intraday trading.” | Vaishali ParekhPrabhudas Lilladher | Piramal Pharma Ltd | MISS | |
| “Initiated coverage on Piramal Pharma with a buy rating and a target price of ₹340. The bullish view is based on signific…” | JM Financial AnalysisJM Financial Institutional Securities | Piramal Pharma Ltd | MISS | |
| “Bullish on Piramal Pharma, raising its target price to ₹310 from ₹260. The firm expects the stock to maintain momentum i…” | Jefferies AnalysisJefferies | Piramal Pharma Ltd | MISS |
Market commentary · 2 · levels, conditionals, previews, macro & hedged views — context, not graded
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Bullish on Piramal Pharma, with its Contract Development and Manufacturing Organisation (CDMO) business performing well,…” | Pankaj PandeyICICI Securities | Piramal Pharma Ltd | — | |
| “Piramal Pharma faces lower risk from potential US tariffs, with 41% US sales. Approximately 50% of its revenue comes fro…” | Jefferies AnalysisJefferies | Piramal Pharma Ltd | — |
Fundamentals
About Piramal Pharma Limited
Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities. It also operates contract development and manufacturing organization that provides services across the drug life cycle, including discovery, development, and commercial manufacturing; offers inhalation anesthetics, intrathecal therapy for spasticity management, injectable pain management drugs, and other generic and speciality products; and analgesics, skin care, vitamin and mineral supplement, kids' wellness, digestives, and women's health, as well as geriatric care. In addition, the company operates as a contract development and manufacturing organization, providing process development, scale-up, and GMP manufacturing services for vaccines and biologics. The company was incorporated in 2020 and is based in Mumbai, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Peter Daniel DeYoung
Headquarters
Mumbai
Employees
7,120
Website
piramalpharma.comExchange
View on NSE ↗Key stats
Market cap
₹31,528.98 Cr
Dividend yield
0.00%
EPS (TTM)
₹-1.58
Beta (1Y · daily vs NIFTY 50)
1.04
Beta (5Y · monthly vs NIFTY 50)
1.44
Shares float
64.46 Cr
EPS · quarter ended Sept 2026
₹0.04
Upcoming earnings
27 Jan 2027
Financial Performance
01 · Financials
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹7,081.55 Cr | ₹8,171.16 Cr | ₹9,151.18 Cr | ₹8,869.08 Cr | |
EBITDA | ₹894.25 Cr | ₹1,366.81 Cr | ₹1,648.91 Cr | ₹993.53 Cr |
| ₹-186.46 Cr | ₹17.82 Cr | ₹91.13 Cr | ₹-325.94 Cr | |
Diluted EPS | ₹-1.54 | ₹0.14 | ₹0.68 | ₹-2.46 |
Net income for Mar 2023 could not be checked against the company's own annual report: this page shows ₹-186.46 Cr while the annual report gives ₹69.50 Cr (137.3% apart).
EBITDA for Mar 2023 could not be checked against the company's own annual report: this page shows ₹894.25 Cr while the annual report gives ₹431.64 Cr (51.7% apart).
09 · Balance Sheet
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹14,522.56 Cr | ₹15,311.81 Cr | ₹15,677.59 Cr | ₹17,965.04 Cr | |
| ₹5,637.08 Cr | ₹4,710.16 Cr | ₹4,856.47 Cr | ₹5,674.58 Cr | |
Stockholders' equity | ₹6,773.50 Cr | ₹7,911.37 Cr | ₹8,125.47 Cr | ₹8,162.62 Cr |
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| — | ₹483.89 Cr | ₹1,004.54 Cr | ₹892.30 Cr | ₹1,652.59 Cr | |
Investing cash flow | — | ₹-1,338.78 Cr | ₹-434.01 Cr | ₹-477.46 Cr | ₹-826.03 Cr |
| — | ₹817.79 Cr | ₹-422.36 Cr | ₹-440.83 Cr | ₹-38.97 Cr | |
Capital expenditure | — | ₹-964.75 Cr | ₹-712.04 Cr | ₹-664.38 Cr | ₹-890.02 Cr |
End cash position | — | ₹53.23 Cr | ₹219.19 Cr | ₹182.32 Cr | ₹976.26 Cr |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt issued, Debt repaid, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Oct 22 | Dec 22–Jun 23(3Q) | Aug 23 | Sep 23–Dec 23(3Q) | Mar 24 | Jun 24 | Sep 24 | Dec 24 | Mar 25 | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 34.79% | 34.79% | 35.02% | 35.02% | 35.02% | 34.95% | 34.95% | 34.95% | 34.95% | 34.86% | 34.86% | 34.86% | 34.86% | 34.80% |
| Public | 64.81% | 64.82% | 64.59% | 64.60% | 64.61% | 64.58% | 64.61% | 64.65% | 64.71% | 64.57% | 64.63% | 64.70% | 64.81% | 64.72% |
| Employee trusts | 0.40% | 0.39% | 0.39% | 0.38% | 0.37% | 0.47% | 0.45% | 0.40% | 0.34% | 0.57% | 0.51% | 0.44% | 0.34% | 0.48% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.25 L Cr | ₹1,769.9 | 38.8 | 5.09 | 13.7% | 0.06 | +11.9% | +3.7% |
| Divi's Laboratories Limited | ₹2.66 L Cr | ₹10,037.5 | 90.8 | 15.85 | 15.3% | 0.00 | +12.3% | +47.5% |
| Torrent Pharmaceuticals Limited | ₹1.79 L Cr | ₹4,738.5 | 79.4 | 21.31 | 25.8% | 1.79 | +21.5% | +32.5% |
| Laurus Labs Limited | ₹1.27 L Cr | ₹2,348 | 94.8 | 23.94 | 16.8% | 0.48 | +22.0% | +146.2% |
| Apollo Hospitals Enterprise Limited | ₹1.23 L Cr | ₹8,599.5 | 58.8 | 12.95 | 20.5% | 0.90 | +15.7% | +10.1% |
| Zydus Lifesciences Limited | ₹1.19 L Cr | ₹1,188.1 | 26.7 | 4.40 | 18.6% | 0.46 | +18.4% | +22.3% |
| Lenskart Solutions Limited | ₹1.16 L Cr | ₹689.7 | 181.4 | 13.30 | 5.6% | 0.35 | +35.4% | — |
| Dr. Reddy's Laboratories Limited | ₹1.14 L Cr | ₹1,374 | 40.6 | 3.02 | 11.4% | 0.21 | +3.2% | +14.5% |
| Cipla Limited | ₹1.13 L Cr | ₹1,402 | 38.9 | 3.27 | 11.3% | 0.02 | +2.1% | -6.7% |
| Mankind Pharma Limited | ₹1.03 L Cr | ₹2,475 | 45.9 | 6.31 | 11.7% | 0.39 | +17.0% | +3.1% |
| Aurobindo Pharma Limited | ₹98,101.93 Cr | ₹1,705 | 26.6 | 2.59 | 9.2% | 0.21 | +6.4% | +48.4% |
| Piramal Pharma Limited | ₹31,530.31 Cr | ₹239.92 | — | 3.86 | -4.0% | 0.70 | -3.3% | +20.2% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Piramal Pharma Share Price Today Down 2.44%: What It Shows
Piramal Pharma shares fell to Rs 189.70, down 2.44% from the prior close of Rs 194.45, after opening near Rs 194.70 and reaching an intraday high of Rs 199.50. The decline occurs amid a large‑cap company reporting a P/B of 3.23x, negative ROE of 4.04% and EPS of Rs ‑2.36, figures that lag industry benchmarks.
Piramal Pharma acquisition: Company to buy remaining 26% stake in Yapan Bio
BusinessLine · 4 days ago